There is currently no antiviral drug licensed by the U.S. Food and Drug Administration (FDA) to treat Ebola infection; however, four drugs called ZMapp remdesivir, Mab114, and REGN-EB3, are under investigation, as each has reduced the risk of death from Ebola [63,64]. This evidence concerns the gene MAPRE3 and Ebola hemorrhagic fever.